ANNUAL REPORT FY2024 11 Other Programs The vast majority of Nyrada’s resources are focused on the advancement of the Brain Injury Program including progressing NYR-BI03 into a Phase I clinical trial. However, in the background and at low cost, Nyrada continues to explore other opportunities. This includes options for the Cholesterol Lowering Program. Nyrada maintains the view that a small molecule oral PCSK9 inhibitor is the optimal treatment for hypercholesterolemia, for which there is a significant growing addressable market driven by demographic, lifestyle, and dietary changes. Corporate Activities In March 2024, following the reporting of its Brain Injury Program preclinical stroke study, the Company raised $1.75 million (before costs) of new equity capital. An additional $0.21 million (before costs) was raised in June 2024 from Board members acquiring stock on the same terms as that for other shareholders ($0.075 per CDI). Nyrada concluded the financial year with AU$4.8 million in cash. Nyrada continues to be disciplined in its capital allocation decisions including maintaining a lean operating model with the vast proportion of resources allocated towards research and development. Conclusion I would like to take this opportunity to extend my appreciation to the Nyrada Board for their ongoing expertise, support, and guidance. Their advice has been instrumental as we work together to execute our strategy, build a great company, improve human outcomes, and create value for our shareholders. I also want to acknowledge the vital role of our Scientific Advisory Board, chaired by Scientia Professor Gary Housley. Their advice and counsel are invaluable. Additionally, I extend my gratitude to the Nyrada team for their diligence and tireless efforts. As we enter the 2025 financial year the team is working hard ahead of our lead Brain Injury Program Candidate, NYR-BI03, entering the clinic. Coupled with the results of our preclinical TBI efficacy study being undertaken with WRAIR, we believe this will open a panoply of opportunities for the company. I am excited for the future of Nyrada and look forward to updating you on our progress at the upcoming Annual General Meeting. James Bonnar Chief Executive Officer
RkJQdWJsaXNoZXIy MjE2NDg3